Tenpoint Therapeutics raises €76.5M Series B round
28 January 2026· London, United Kingdom· health, ophthalmology, biotech, cell_therapy, b2b, deep_hardware
The financing, which included $85 million in equity and a $150 million debt facility, is intended to support the commercial launch of YUVEZZI (an FDA-approved eye drop for presbyopia) and the advancement of pipeline programs for age-related eye diseases.
Investors
LeadJanus Henderson
Also participating
Eight RoadsSofinnova PartnersBritish Business BankEQT Life SciencesF-Prime CapitalWille FinanceHillhouseAdBio PartnersEQT NexusQiming Venture Partners USAImpresa Management LLC
About Tenpoint Therapeutics
Stage
Series B
Headquarters
London, United Kingdom
Founded
2020
Team Size
51–200
Sectors
healthophthalmologybiotechcell_therapyb2bdeep_hardware